Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EPS (Basic) (2016 - 2025)

Collegium Pharmaceutical has reported EPS (Basic) over the past 10 years, most recently at $0.54 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.54 for Q4 2025, up 38.46% from a year ago — trailing twelve months through Dec 2025 was $2.0 (down 6.54% YoY), and the annual figure for FY2025 was $1.98, down 7.48%.
  • EPS (Basic) for Q4 2025 was $0.54 at Collegium Pharmaceutical, down from $1.0 in the prior quarter.
  • Over the last five years, EPS (Basic) for COLL hit a ceiling of $2.06 in Q2 2021 and a floor of -$0.73 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was $0.38 (2023), compared with a mean of $0.34.
  • Biggest five-year swings in EPS (Basic): plummeted 465.0% in 2021 and later skyrocketed 6000.0% in 2023.
  • Collegium Pharmaceutical's EPS (Basic) stood at -$0.73 in 2021, then soared by 71.23% to -$0.21 in 2022, then soared by 571.43% to $0.99 in 2023, then crashed by 60.61% to $0.39 in 2024, then skyrocketed by 38.46% to $0.54 in 2025.
  • The last three reported values for EPS (Basic) were $0.54 (Q4 2025), $1.0 (Q3 2025), and $0.38 (Q2 2025) per Business Quant data.